CD274 and neoplasm: Although molecular markers such as programmed cell death‐ligand 1 (PD‐L1) expression and tumor mutational burden (TMB) show promise, their clinical application remains limited due to challenges such as tissue sampling, invasiveness, and high costs [3, 4].